- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- Fed Sanguine About US Recovery, Worried on Jobs
- Amended Berkshire Filing Reveals No 'Secret' Holdings
- Holiday Guide to This Season's Smartphones
- In Time for Holidays: More Gloom and Doom on Economy
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wednesday's Economic News Crunch Could Tilt Markets
- NBA D-League On The Rise
- Australia Wheat Exporters Face Challenges: GrainCorp
- Stifling Anger at Work Can Kill, Survey Finds
- Japan Export Rebound Eases Fear of New Recession
- Trading Block
- Obama Reiterates Commitment to Boost US-India Ties
- Confessions of a Black Friday Shopper
- China Shipbuilding to Launch $937 Million China IPO
Text Size 
Genentech's [DNA
Loading...
()
] asthma drug Xolair should carry the strongest warning possible about the drug's risk of a serious reaction known as anaphylaxis, U.S. health regulators said Wednesday.
The Food and Drug Administration said anaphylaxis -- a severe allergic reaction -- could occur as late as 24 hours after patients take any amount of the drug, also known as omalizumab. The agency added that doctors and patients should be prepared to treat the reaction, which can cause breathing problems, fainting and hives.
In a statement, the South San Francisco-based biotech said it was still discussing the request for a so-called black box warning with the FDA. "The updated wording and its placement in the label is not yet final," the company said.
Genentech is majority-owned by Swiss drugmaker Roche Holding.
Reports of the reaction to Xolair were seen in clinical trials before the drug was approved in 2003 to treat patients with allergy-related asthma, the FDA said. About one in a thousand patients experienced it.
Continued reports of the problem after that prompted the agency's call for the tough warning given "their life-threatening potential, frequency, and the possibility for the delayed onset of anaphylaxis," the agency added.
Print
Email
- Remember when auto shows were major events where new models could generate buzz?
- CNBC’s Mike Huckman visits a cutting-edge plant to see how the flu vaccine of the future is being made.
- People who bottle up their anger at work are up to five times more likely to suffer a heart attack, a study found.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- A new McDonald's in Manhattan is the nation's first to sport a sleek, chic interior imported from stores in London and Paris.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes